IOL Chemicals and Pharmaceuticals Limited's product, "Ibuprofen," has received approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China.

The company has reported total income of Rs. 500.80 crores during the period ended March 31, 2025 as compared to Rs. 483.54 crores during the period ended December 31, 2024. The company has posted ...

The company has reported total income of Rs. 1798.2 crores during the period ended March 31, 2025 as compared to Rs. 1784.9 crores during the period ended December 31, 2024. The company has posted ...

The Board of Directors of RBL Bank Limited, at its meeting held today have approved the financial results of the company for ...

The Board of Directors of DCB Bank Limited, at its meeting held today have approved the financial results of the company for ...

The Board of Directors of VST Industries Limited, at its meeting held today have approved the financial results of the ...

The company has reported total income of Rs. 55.44 crores during the period ended March 31, 2025 as compared to Rs. 185.77 crores during the period ended December 31, 2024. The company has posted ...